Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:24:56 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:CYTK - CYTOKINETICS INC - https://www.cytokinetics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYTK - Q0.161.01·62.950.162.34+2.103.51,735.6105,11219,18061.31  62.74  61.0070.98  29.3119:39:09Jan 2715 min RT 2¢

Recent Trades - Last 10 of 19180
Time ETExPriceChangeVolume
19:39:09Q61.000.761,000
17:54:40Q61.130.8910
17:34:16Q62.502.26150
17:33:51Q62.502.26150
16:29:34Q61.321.081
16:24:36Q61.881.641
16:24:36Q61.321.0818
16:24:36Q61.140.901
16:12:49Q61.140.901
16:12:28Q62.342.10700

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-27 08:00U:CYTKNews ReleaseCytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
2026-01-27 07:30U:CYTKNews ReleaseCytokinetics Announces MYQORZO(TM) (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
2026-01-20 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-05 16:00U:CYTKNews ReleaseCytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-19 16:00U:CYTKNews ReleaseCytokinetics Announces FDA Approval of MYQORZO(TM) (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
2025-12-17 07:30U:CYTKNews ReleaseCytokinetics Announces NMPA Approval of MYQORZO(TM) (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
2025-12-16 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-12-12 08:43U:CYTKNews ReleaseCytokinetics Announces Positive CHMP Opinion of MYQORZO(TM) (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
2025-11-18 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-11-17 08:10U:CYTKNews ReleaseCytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy
2025-11-10 07:30U:CYTKNews ReleaseCytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
2025-11-05 16:00U:CYTKNews ReleaseCytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-04 16:00U:CYTKNews ReleaseCytokinetics to Participate in November Investor Conferences
2025-10-31 07:30U:CYTKNews ReleaseCytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
2025-10-22 16:00U:CYTKNews ReleaseCytokinetics to Announce Third Quarter Results on November 5, 2025
2025-10-17 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-09-29 07:31U:CYTKNews ReleaseCytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025
2025-09-24 07:30U:CYTKNews ReleaseCytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
2025-09-23 16:00U:CYTKNews ReleaseCytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
2025-09-18 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)